DD
Therapeutic Areas
TheracosBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Brenzavvy (bexagliflozin) | Type 2 Diabetes | Approved |
Leadership Team at TheracosBio
BC
Brian Connelly
President and CEO
JB
Jeffrey B. McGroarty
Chief Financial Officer
JB
Jeffrey B. Prince
Intellectual Property and Communications
SP
Srinivasa Peddi
Regulatory Affairs
TK
Tara K. Thurber
Clinical Operations
JC
Joseph Chau
Chemistry, Manufacturing and Controls
RB
Roland Bizanek
Quality Assurance